Targeting DNA binding proteins for cancer therapy.

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Dysregulation of DNA-binding proteins, including transcription factors (TFs), is implicated in the initiation and progression of diseases like cancer.
• TF activity alterations in cancer arise from genetic changes (amplification, deletion, mutation) and epigenetic modifications.
• Targeting cancer-associated TFs holds therapeutic promise, but drug development has been hindered by a lack of effective screening methods.

Purpose of the Study:

• To review known cancer-associated transcription factors categorized by cancer type.
• To introduce recent high-throughput screening approaches for identifying selective inhibitors of these TFs.
• To highlight advancements enabling novel therapeutics targeting cancer-associated TFs.

Main Methods:

• Literature review of cancer-associated transcription factors.
• Summary of recent technological advancements in DNA-binding protein identification.
• Overview of high-throughput screening methodologies for TF inhibitor discovery.

Main Results:

• Compilation of cancer-associated TFs across various cancer types.
• Identification of emerging high-throughput screening techniques.
• Demonstration of feasibility in developing selective inhibitors for cancer-associated TFs.

Conclusions:

• Recent technological progress facilitates the development of targeted cancer therapies.
• High-throughput screening methods are crucial for identifying selective inhibitors of cancer-associated TFs.
• Targeting transcription factors represents a promising avenue for future cancer therapeutics.